AU2022386352B2 - Preserved formulations - Google Patents

Preserved formulations

Info

Publication number
AU2022386352B2
AU2022386352B2 AU2022386352A AU2022386352A AU2022386352B2 AU 2022386352 B2 AU2022386352 B2 AU 2022386352B2 AU 2022386352 A AU2022386352 A AU 2022386352A AU 2022386352 A AU2022386352 A AU 2022386352A AU 2022386352 B2 AU2022386352 B2 AU 2022386352B2
Authority
AU
Australia
Prior art keywords
concentration
composition
insulin
phenol
benzyl alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2022386352A
Other languages
English (en)
Other versions
AU2022386352A1 (en
Inventor
David Paul ALLEN
John Michael Beals
Vincent John Corvari
Patrick Daniel Donovan
Ken Kangyi Qian
Wei Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2022386352A1 publication Critical patent/AU2022386352A1/en
Application granted granted Critical
Publication of AU2022386352B2 publication Critical patent/AU2022386352B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022386352A 2021-11-15 2022-11-14 Preserved formulations Active AU2022386352B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163279390P 2021-11-15 2021-11-15
US63/279,390 2021-11-15
PCT/US2022/079791 WO2023086980A1 (en) 2021-11-15 2022-11-14 Preserved formulations

Publications (2)

Publication Number Publication Date
AU2022386352A1 AU2022386352A1 (en) 2024-05-09
AU2022386352B2 true AU2022386352B2 (en) 2025-12-18

Family

ID=84537390

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022386352A Active AU2022386352B2 (en) 2021-11-15 2022-11-14 Preserved formulations

Country Status (19)

Country Link
US (1) US20250000950A1 (https=)
EP (1) EP4433024A1 (https=)
JP (1) JP2024543457A (https=)
KR (1) KR20240082407A (https=)
CN (1) CN118302152A (https=)
AR (1) AR127619A1 (https=)
AU (1) AU2022386352B2 (https=)
CA (1) CA3238180A1 (https=)
CL (1) CL2024001415A1 (https=)
CO (1) CO2024006121A2 (https=)
CR (1) CR20240202A (https=)
DO (1) DOP2024000084A (https=)
EC (1) ECSP24036789A (https=)
IL (1) IL312623A (https=)
JO (1) JOP20240108A1 (https=)
MX (1) MX2024005879A (https=)
PE (1) PE20241354A1 (https=)
TW (1) TWI871539B (https=)
WO (1) WO2023086980A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130011378A1 (en) * 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8097584B2 (en) * 2005-05-25 2012-01-17 Novo Nordisk A/S Stabilized formulations of insulin that comprise ethylenediamine
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
CN103509118B (zh) 2012-06-15 2016-03-23 郭怀祖 胰岛素-Fc融合蛋白
AR091902A1 (es) * 2012-07-25 2015-03-11 Hanmi Pharm Ind Co Ltd Formulacion liquida de un conjugado de insulina de accion prolongada
AR105616A1 (es) * 2015-05-07 2017-10-25 Lilly Co Eli Proteínas de fusión
JP2020513019A (ja) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス オリゴマー伸長インスリン−Ｆｃコンジュゲート
KR20210029210A (ko) 2018-06-29 2021-03-15 악스톤 바이오사이언시스 코퍼레이션 초장기 작용 인슐린-fc 융합 단백질 및 사용 방법
WO2020074544A1 (en) 2018-10-10 2020-04-16 Novo Nordisk A/S Oligomer extended insulin-fc conjugates and their medical use
US20220354782A1 (en) * 2019-09-17 2022-11-10 Cass Pharmaceuticals, Inc. Subcutaneously injectable insulin and glucagon formulations and methods of administration
WO2021119607A1 (en) * 2019-12-13 2021-06-17 The Board Of Trustees Of The Leland Stanford Junior University Stable monomeric insulin formulations enabled by supramolecular pegylation of insulin analogues
KR20250142943A (ko) 2019-12-19 2025-09-30 악스톤 바이오사이언시스 코퍼레이션 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130011378A1 (en) * 2011-06-17 2013-01-10 Tzung-Horng Yang Stable formulations of a hyaluronan-degrading enzyme

Also Published As

Publication number Publication date
TW202339790A (zh) 2023-10-16
JOP20240108A1 (ar) 2024-05-14
KR20240082407A (ko) 2024-06-10
ECSP24036789A (es) 2024-06-28
PE20241354A1 (es) 2024-07-03
MX2024005879A (es) 2024-05-29
CR20240202A (es) 2024-06-11
CL2024001415A1 (es) 2024-10-18
CN118302152A (zh) 2024-07-05
DOP2024000084A (es) 2024-06-16
EP4433024A1 (en) 2024-09-25
AU2022386352A1 (en) 2024-05-09
AR127619A1 (es) 2024-02-14
IL312623A (en) 2024-07-01
JP2024543457A (ja) 2024-11-21
US20250000950A1 (en) 2025-01-02
WO2023086980A1 (en) 2023-05-19
CO2024006121A2 (es) 2024-06-27
TWI871539B (zh) 2025-02-01
CA3238180A1 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
KR101084412B1 (ko) 코팅된 제약 용기 내 안정화된 액상 단백질 제제
EP2586459B1 (en) Vegf antagonist formulations
JP5941496B2 (ja) 成長ホルモン製剤
AU2017225236B2 (en) A lyophilised pharmaceutical formulation and its use
AU2022386352B2 (en) Preserved formulations
HK40077155A (en) A lyophilised pharmaceutical formulation and its use
ZA200200176B (en) Growth hormone formulations.
HK1184680B (en) Vegf antagonist formulations
HK1088558B (en) Liquid stabilized protein formulations in coated pharmaceutical containers

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)